VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Vaccine Mechanisms
VaximmutorDB
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Mycobacterium tuberculosis drrC mutant vaccine
Vaccine Information
  • Vaccine Name: Mycobacterium tuberculosis drrC mutant vaccine
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0002780
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • drrC gene engineering:
    • Type: Gene mutation
    • Description: This drrC mutant is from Mycobacterium tuberculosis (Pinto et al., 2004).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intravenous injection (i.v.)
Host Response

Mouse Response

  • Persistence: A drrC mutant is highly attenuated in mice (Pinto et al., 2004).
  • Efficacy: A drrC mutant induces significant protection in mice from challenge with wild type M. tuberculosis (Pinto et al., 2004).
  • Host Ifng (Interferon gamma) response
    • Description: The drrC− strain was able to induce splenic anti–M. tuberculosis IFN-γ–secreting T cells responsive to CFP in mice to a level equal to that induced by M. tuberculosis infection and much greater than the amount induced by BCG and control mice. The drrC− mutant was also able to generate high numbers of IFN-γ–secreting cells that recognize the M. tuberculosis ESAT-6 antigen, which BCG and control mice could not do. IFN-gamma levels in both cases were comparable to levels induced by the wild type. This effect began 4 weeks after infection and was sustained long-term (24 weeks after infection) (Pinto et al., 2004).
    • Detailed Gene Information: Click Here.
  • Information about this animal model: Mouse Model for TB research
References
Pinto et al., 2004: Pinto R, Saunders BM, Camacho LR, Britton WJ, Gicquel B, Triccas JA. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine. The Journal of infectious diseases. 2004; 189(1); 105-112. [PubMed: 14702160].